Obesity Clinical Trial
Official title:
Blood Glucose Variability in Obese Youth Participating in a Lifestyle Modification Program
The purpose of this study is to measure blood glucose variation in youth prior to and after participation in a healthy lifestyle intervention program. The hypothesis is that youth with more severe obesity and those further along in puberty will have more glycemic variability, and that glycemic variability will be improved by participation in the lifestyle intervention program.
Healthy lifestyle intervention programs aim to increase exercise and teach youth and about
healthier dietary options, in hopes of avoiding obesity complications such as diabetes, and
addressing the root causes of obesity. The program entitled Bright Bodies: A Lifestyle
Intervention Program for Obese Youth, has been tested rigorously, showing significant
improvements in body mass index and insulin resistance at both 1 and 2 years after the
program and reversal of early abnormalities in glucose metabolism. While abnormalities on
standardized oral glucose tolerance testing are well described in obese youth, this test may
not reflect the "real life" glycemia changes in obese children. Understanding early glycemic
changes in obese youth is important to better identify those at risk and strategize effective
treatment plans, to avoid progression to prediabetes and diabetes. Thus the use of a
continuous glucose monitor (CGM) may be a helpful adjunct to understanding the disease and
therapy approaches in these patients.
A CGM is a device inserted under the skin on the abdomen which monitors glucose levels every
5 minutes, recording this information. CGM is commonly worn by kids with type 1 diabetes. The
study will allow collection of information on glucose variability in much greater detail than
can be seen from intermittent fingerstick glucose values or from an oral glucose tolerance
test. Given the widespread epidemic of obesity and its complications, the ability to
illustrate glycemic variability in obese youth is key to delineating risk categories and
optimizing treatment. While lifestyle modification programs can be effective in improving
measures of insulin sensitivity and OGTT results, their effect on real life glucose values
has not been described. Hence the current study, aims to describe day-to-day glycemic
variation in obese youth using CGM.
All enrolled subjects will wear a CGM for up to 7 days prior to initiation of the Bright
Bodies program, and for up to 7 days at the end of the program. Additionally subjects will
complete a food record and report exercise during both study periods. The study periods will
take place during the 2 months prior to and the 2 months after completing the Bright Bodies
program. The study will be explained to volunteers who meet eligibility criteria and informed
consent/assent will be obtained. Demographic data will be recorded. Medical history will be
obtained and a brief physical exam may be performed. Height, weight, BMI, percent body fat,
fat mass, and fat free mass will be measured.
After enrollment subjects will meet with study personnel and learn how to keep a food record,
with intermittent phone contact by study personnel to optimize food record compliance. They
will also be asked to record exercise and any medications taken. A blinded CGM will be
inserted at the beginning of each study period. Subjects will be educated regarding the CGM,
including the requirement to measure blood glucose levels with a glucometer 3 times a day, at
least every 12 hours (ideally on waking in the morning before eating, before dinner, and
before bedtime), to calibrate the sensor. Subjects will be given a glucometer to obtain
fingerstick blood sugar values and receive instruction regarding its use.
During the follow up visits the CGM will be removed, and the CGM and glucometer will be
downloaded and collected. The food record will be collected.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |